Knopp Biosciences: Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 Demonstrating That Oral Dexpramipexole Improves Airflow Obstruction as Measured by Forced Expiry Volume (FEV1), Largely Through Its Effect on Forced Vital Capacity (FVC)

Press Release: Knopp Biosciences : Knopp Biosciences NIH-funded Pain Program Advances to Third Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain

Knopp Biosciences: Knopp Biosciences LLC: Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating that Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung Function

Knopp Biosciences: Knopp Biosciences Reports Positive Results From the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021

Knopp Biosciences: Knopp Biosciences LLC: Knopp Biosciences to Present Details of Positive Results From the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021

Press Release: Knopp Biosciences : Knopp Biosciences Launches New Website with Digital Silk Showcasing Innovative Medical Science and Drug Development

Knopp Biosciences: Knopp's oral asthma drug hits primary endpoint in phase 2